POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy

Inclusion Criteria: Patients aged 18 years or older are eligible for inclusion if all of the following criteria are met: * Clinical diagnosis of NSTE-ACS (i.e. NSTEMI or unstable angina) * Successful PCI (according to the treating physician) with implantation of new generation drug eluting stents. * CYP2C19 extensive or ultra-rapid metabolizer Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: * CYP2C19 poor or intermediate metabolizer * Known allergy or contraindication for aspirin or clopidogrel. * Concurrent use of oral anticoagulants (e.g. because of atrial fibrillation) * Ongoing indication for DAPT at admission (e.g. due to recent PCI or ACS) * High-risk features for PCI including left main disease, chronic total occlusion, bifurcation lesion requiring 2-stent treatment, saphenous or arterial graft lesion, severely calcified lesion requiring the use of the Rotablator system, ≥3 treated vessels, ≥ 3 stents implanted and total stent length \>60 mm * Recent stroke, transient ischemic attack (TIA) or intracranial bleeding * Severe hepatic impairment (Child Pugh class C) * Planned surgical intervention within 6 months of PCI * Patients requiring staged procedure (to avoid heterogeneity in the duration of pharmacological treatment between index and staged procedures) * Pregnant or breastfeeding women at time of enrolment * Participation in another trial with an investigational drug or device